ArticleScientific reports2026
Niosomal l-carnitine and quercetin improve sperm quality and testicular function in atrazine-induced reproductive toxicity in rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrazine (ATZ), a frequently employed herbicide, is classified as one of the environmental pollutants that play a pivotal role in progression of male infertility. L-carnitine (LC) and quercetin (QT) possess antioxidant properties, rendering them viable additional treatments for male infertility. Additionally, specialized drug delivery systems, such as niosomes, enhance the distribution of hydrophilic pharmaceuticals. This study aimed to investigate the ameliorative potential of LC and QT, administered in conventional and niosomal formulations, against ATZ-induced testicular dysfunction in adult male albino rats. Thirty rats were randomly assigned to six experimental groups: control, ATZ, ATZ + LC, ATZ + LC-loaded niosomes (LCLN), ATZ + QT, and ATZ + QT-loaded niosomes (QTLN). Treatments were administered orally for 56 consecutive days. Biochemical analyses, sperm evaluations, gene expression assessments, and histopathological measures were conducted. ATZ exposure significantly decreased absolute and relative seminal vesicle weights, impaired sperm motility, viability, morphology and count, and reduced circulating testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) concentrations. Moreover, ATZ markedly elevated malondialdehyde levels, suppressed the activities of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase), and downregulated the transcription of key steroidogenic genes (HSD3B, StAR and CYP11A1). Histopathological assessment further revealed pronounced degenerative changes in the testes, epididymis, seminal vesicles, and prostate. Co-administration of LC or QT, particularly in niosomal formulations, significantly attenuated these deleterious effects. They restored sperm quality, re-established redox homeostasis, normalized steroidogenic gene expression, and preserved the structural integrity of reproductive tissues. In conclusion, niosomal formulations of LC and QT confer superior protective efficacy against ATZ-induced testicular toxicity compared to their conventional counterparts, underscoring their therapeutic potential as targeted interventions against environmental toxicants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.